Letter to the Editor Concerning "Glycosylated Hemoglobin as a Surrogate for the Prediction of Cardiovascular Events in Cardiovascular Outcome Trials Comparing New Antidiabetic Drugs to Placebo"
- PMID: 32353845
- DOI: 10.1159/000507507
Letter to the Editor Concerning "Glycosylated Hemoglobin as a Surrogate for the Prediction of Cardiovascular Events in Cardiovascular Outcome Trials Comparing New Antidiabetic Drugs to Placebo"
Comment in
-
Authors' Reply to the Letter by Shoar et al. on "Glycosylated Hemoglobin as a Surrogate for the Prevention of Cardiovascular Events in Cardiovascular Outcome Trials Comparing New Antidiabetic Drugs to Placebo".Cardiology. 2020;145(6):387. doi: 10.1159/000507361. Epub 2020 May 8. Cardiology. 2020. PMID: 32388505 No abstract available.
Comment on
-
Glycosylated Hemoglobin as a Surrogate for the Prevention of Cardiovascular Events in Cardiovascular Outcome Trials Comparing New Antidiabetic Drugs to Placebo.Cardiology. 2020;145(6):370-374. doi: 10.1159/000506004. Epub 2020 Feb 21. Cardiology. 2020. PMID: 32088710
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
